Abstract
Chronic beta-AR activation is detrimental because it promotes cardiac remodeling and ultimately leads to heart failure (HF). Multiple cyclic nucleotide phosphodiesterases (PDEs) finely tune beta-AR responses by degrading and compartmentalizing cAMP. Since chronic treatment with PDE inhibitors increases mortality in HF, we postulated that decreasing cAMP levels by overexpressing PDE4B in the heart may have therapeutic effects. To test this hypothesis, we explored whether AAV9-mediated cardiac overexpression of PDE4B (10 12 viral particles) could prevent maladaptive hypertrophy in mice subjected either to transverse aortic constriction (TAC) for 6 weeks or 2 weeks isoproterenol (Iso) and phenylephrine (Phe) infusion (30μg/g/day each). Cardiac function was assessed by echocardiography. In control mice injected with a Luciferase-AAV9 (LUC), TAC decreased ejection fraction (EF, - 34.2 ± 6%, N = 6, P < 0.0001), increased left ventricular weight/body weight ratio (LVW/BW, + 86.7 ± 15.7%, N = 6, P < 0.0001). Although PDE4B overexpression did not ameliorate EF, it delayed the decrease of EF at 2 weeks ( N = 9, P < 0.05), prevented LV hypertrophy ( N = 9, P < 0.001) and fibrosis ( N = 9, P < 0.05). Chronic Iso and Phe treatment induced LV hypertrophy (LVW/BW, + 37.8 ± 6.2%, N = 7, P < 0.001) and decreased EF (- 25 ± 3.5%, N = 7, P < 0.0001). While PDE4B overexpression only slightly ameliorated EF (- 17 ± 3%, N = 9) in this model, LV hypertrophy was significantly diminished ( N = 9, P < 0.05). PDE4B protein level was assessed by western blotting and revealed a ∼6 to 9-fold increased expression in both HF models. We are currently analyzing whether PDE4B overexpression can prevent fibrosis induced by catecholamines and limit ventricular arrhythmias induced by catheter-mediated burst pacing following intraperitoneal injection of isoprenaline. Altogether, our preliminary results suggest that gene therapy with PDE. Chronic ß-AR activation is detrimental because it promotes cardiac remodeling and ultimately leads to heart failure (HF). Multiple cyclic nucleotide phosphodiesterases (PDEs) finely tune ß-AR responses by degrading and compartmentalizing cAMP. Since chronic treatment with PDE inhibitors increases mortality in HF, we postulated that decreasing cAMP levels by overexpressing PDE4B in the heart may have therapeutic effects. To test this hypothesis, we explored whether AAV9-mediated cardiac overexpression of PDE4B (10 12 viral particles) could prevent maladaptive hypertrophy in mice subjected either to transverse aortic constriction (TAC) for 6 weeks or 2 weeks isoproterenol (Iso) and phenylephrine (Phe) infusion (30μg/g/day each). Cardiac function was assessed by echocardiography. In control mice injected with a Luciferase-AAV9 (LUC), TAC decreased ejection fraction (EF, -34.2 ± 6%, N = 6, P < 0.0001), increased left ventricular weight/body weight ratio (LVW/BW, + 86.7 ± 15.7%, N = 6, P < 0.0001). Although PDE4B overexpression did not ameliorate EF, it delayed the decrease of EF at 2 weeks ( N = 9, P < 0.05), prevented LV hypertrophy ( N = 9, P < 0.001) and fibrosis ( N = 9, P < 0.05). Chronic Iso and Phe treatment induced LV hypertrophy (LVW/BW, + 37.8 ± 6.2%, N = 7, P < 0.001) and decreased EF (- 25 ± 3.5%, N = 7, P < 0.0001). While PDE4B overexpression only slightly ameliorated EF (- 17 ± 3%, N = 9) in this model, LV hypertrophy was significantly diminished ( N = 9, P < 0.05). PDE4B protein level was assessed by western blotting and revealed a ∼6 to 9-fold increased expression in both HF models. We are currently analyzing whether PDE4B overexpression can prevent fibrosis induced by catecholamines and limit ventricular arrhythmias induced by catheter-mediated burst pacing following intraperitoneal injection of isoprenaline. Altogether, our preliminary results suggest that gene therapy with PDE4B is a potential therapeutic approach for cardiac maladaptive hypertrophy.4B is a potential therapeutic approach for cardiac maladaptive hypertrophy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.